Tris Pharma

US Highway 130
Monmouth Junction
NJ
08852
United States

Tel: (732) 940-2800

About Tris Pharma

Founded in 2000, Tris Pharma, Inc. (www.trispharma.com) is the 3rd largest specialty pharmaceutical company in the United States. With our intense focus on the application of physical chemistry in biological systems, coupled with the requirements of manufacturing and market demands, we have grown our employee base over 250% in the past three years. Specifically, we are engaged in research, development, and manufacturing of both OTC and Rx branded products and specialty generic products. Our mission is to understand the science driving the delivery of drugs into the human body;develop and bring to market products that add value to our customers and patients and provide a benefit to our company, employees and society at large.

70 articles with Tris Pharma

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance

8/27/2018

Tris Pharma, Inc. today announced the joining of Jeffery Palmer as its new Vice President and Head of Quality & Compliance.
Tris Pharma, Inc. Appoints New Chief Commercial Officer For Brand Business

3/10/2017
Tris Pharma, Inc.’s Results From A Laboratory Classroom Study Of DYANAVEL XR In Children With ADHD Featured At APSARD

2/9/2017
Tris Pharma, Inc. Release: FDA Accepts CCP-08 NDA For Full Review

12/21/2016
Tris Pharma, Inc. Announces The Launch Of DYANAVEL XR (Amphetamine) Extended-Release Oral Suspension, CII For The Treatment Of Children With ADHD

4/19/2016
Tris Pharma, Inc. Announces Appointment Of Chief Commercial Officer Of Its New Brand Business

4/7/2016
Tris Pharma, Inc. Announces First Ever FDA-Approved Extended-Release Chewable Tablet

12/16/2015
Tris Pharma, Inc. Receives FDA Approval Of Dyanavel XR (amphetamine) CII As Once-Daily Liquid For Treatment Of ADHD In Children

10/20/2015
Tris Pharma, Inc. Launches Generic Tussionex As Par's Rights Expire

10/1/2015
Tris Pharma, Inc. And Pfizer Consumer Healthcare Enter Into Agreement To Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup Under The Robitussin Brand

6/29/2015
Tris Pharma, Inc. Announces The FDA Acceptance Of NDA For Dyanavel XR

5/21/2015
Vernalis PLC And Tris Pharma, Inc. Receive FDA Approval Of NDA For Tuzistra XR (Codeine Polistirex And Chlorpheniramine Polistirex)

5/1/2015
Tris Pharma, Inc. Selected As An Award Winner In The New Jersey Business & Industry Association's 2014 Awards For Excellence

8/27/2014
Vernalis PLC And Tris Pharma, Inc. Release: Submission Of Tuzistra XR (CCP-01) NDA To FDA

6/30/2014
Tris Pharma, Inc. Expands R&D Team With Addition Of Chief Medical Officer And Vice President Of Regulatory Affairs

6/26/2014
Tris Pharma, Inc. Announces Management Changes

4/1/2014
Tris Pharma, Inc. and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal&#0153 ER (carbinoxamine maleate) Extended-Release Oral Suspension

9/4/2013
Tris Pharma, Inc.'s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution

7/10/2013
Tris Pharma, Inc. Hires President for Generic Pharmaceuticals Business

6/20/2013
Tris Pharma, Inc.'s Ketan Mehta Among Ernst & Young LLP Entrepreneur of the Year&#0174 2013 Finalists in New Jersey

5/2/2013